“Our purpose is to enable people with lifealtering conditions to lead better lives,” Says Vineet Singhal, Country Head, Baxalta Bioscience India Pvt Ltd (Now part of Shire). in an exclusive interview with Mahesh Kallayil, he further talks about potential oppor tunit ies in rare disease market, ensuring affordability of specialty medicines, business strategies and much more.
Can you briefly explain about Shire's vision and its focus areas in India?
Shire is a leading global biotechnology company committed to serving people affected with rare diseases and other highly specialized conditions. These diseases (many of which are genetic) are often misunderstood, undiagnosed, and potentially life-threatening.
Shire keeps patients at the centre of everything we do. In India, we are focused on two therapeutic categories, one being Hematology with our portfolio covering antihemophilia factors. Hemophilia is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII ) Hemophilia A or factor IX (FIX) Hemophilia B. The deficiency is the result of mutations of the respective clotting factor genes.
The second broad franchise in India is Immunology where we sell high-quality albumin and immunoglobulins, which are used under critical care by leading hospitals across India. We have widened our reach across the country and are present in every state.
How do you see rare disease market in India?
The biggest challenge that we see is that awareness and understanding of most rare diseases remains limited in India.
Therefore our primary focus will be on three areas: the first is to increase awareness of these conditions amongst the medical community. Our second focus will be to improve the means of diagnosis for rare diseases. Thirdly and most importantly we want to make therapies accessible to patients.
Denne historien er fra June 2017-utgaven av Pharma Bio World.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra June 2017-utgaven av Pharma Bio World.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
B&R Expands Gilgenberg Site
Automation specialist invests in production, office space and logisticsB&R is investing in its Gilgenberg site, located a few kilometers from the B&R headquarters in Eggelsberg. The expansion adds new offices, training rooms and production space. A new logistics hall has also been opened at the site.
Creating An Annual Event Of The Biopharma Industry By Focusing On Frontiers, & Promoting Leading Enterprises To Collaborate
The Union Budget 2018 was presented on February 1, 2018.
Pain Point To Gaining Brownie Points: Technology Is A Game Changer For Indian Pharma Sector
The Indian pharmaceutical industry has come a long way from traditional home-made herbal medicines to being the manufacturer of world class life-saving drugs. However, at the helm of game-changing innovations steering this industry to a whole new level is the implementation of technology.
Data Acquisition, Evaluation And Transmission To The Cloud
A single device to acquire data, evaluate it and send it to the cloud – that’s now possible with B&R’s Edge Controller. The powerful industrial PC can even be used for big data analysis and machine learning, while at the same time serving as a full-fledged industrial controller.
Just The Right Dose Of Intelligence
Nothing herein shall constitute an offer to sell, or a solicitation of an offer to buy. The ACOPO Strak product is not available for sale into the United States of America until September 2018.
Considerations For Extraction, Stabilization And Quantification By PCR For Sensitive Sample Such As RNA
This article talks about careful selection of an extraction system that helps stabilize and protect targets, especially RNA, or which allows for immediate analysis.
Novel Research In Pharmaceuticals And Bio-Pharmaceuticals
This article covers entire spectra of pharmaceutical research and as well as those related to synthesis and processing of pharmaceuticals.
Boost Productivity With Anti-sloshing
Transport liquids faster without spills With B&R’s industrial transport system, it is now possible to transport liquids quickly with no spills. SuperTrak is the only system on the market to offer anti-sloshing technology. This technology suppresses the format ion of oscillations on free surfaces to prevent liquids from spilling over container edges during transport .
Rational Use Of Drugs And Irrational Drug Combinations
Irrational use of medicines is a global phenomenon. Rational use of drugs may be defined as: Patients receive medications appropriate to their clinical needs, in doses that meet their own individual requirements, for an adequate period of time, and the lowest cost to them and their community. Overuse, polypharmacy and incorrect use of drugs are the most common problems of drug use today. Irrational use of drugs may result due to various reasons at various levels including the prescribing errors and over the counter drugs. Irrational use of medicines may lead to serious negative health and economic consequences. Many irrational drug combinations are available in the Indian market. Proper implementation of rational use of drugs will improve the quality of life and result in better community healthcare.
Cold Chain Management For Sensitive Goods
Packaging, route planning and risk analysis ensure safe conditions during transportation of delicate drugs. Drugs are sensitive goods to transport, which can be subject to irreversible damage if they are stored or transported at temperatures outside the tolerated range. If the temperature falls below or rises above the specified range the quality of drugs requiring refrigeration can be seriously affected and they may cease to be effective. This article therefore describes how transport conditions during the transportation of drugs can be optimised through suitable packaging, individualised process design, the analysis and assessment of potential risks and close collaboration between the sender and the freight carrier.
